Kohla Samah, Ibrahim Feryal A, Aldapt Mahmood B, ELSabah Hesham, Mohamed Shehab, Youssef Reda
Department of Lab Medicine and Pathology, Hematology Division, Hamad Medical Corporation, Doha, Qatar.
Department of Clinical Pathology, Hematology Division, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.
Case Rep Oncol. 2020 Dec 4;13(3):1430-1440. doi: 10.1159/000512830. eCollection 2020 Sep-Dec.
Coronavirus disease 2019 (COVID-19) pandemic has been a serious threat and has been reported with different presentations and complications. Older age, along with comorbidities such as diabetes, hypertension, or cardiac disease, increases the risk factors for COVID-19 severity and death [N Engl J Med. 2020;382(18):1708-20 and Lancet Respir Med. 2020 05;8(5):475-81]. It is proposed that cancer patients have a significantly higher incidence of severe incidents including admission to the intensive care unit, the necessity for assisted ventilation, and even death after catching the virus compared with non-cancer patients [Lancet Oncol. 2020;21(3):335-7]. It is also described that cancer patients appear to be twice as likely to contract infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) [JAMA Oncol. 2020;6(7):1108-10]. Hairy cell leukemia (HCL) is a rare B-cell lymphoproliferative disorder, with patients typically presenting with cytopenias, marked splenomegaly in 80-90% of patients, circulating leukemia cells, bone marrow infiltration and the presence of BRAF V600E somatic mutation [Indian J Hematol Blood Transfus. 2014;30(Suppl 1):413-7]. Leukemic cells classically have central nuclei and abundant cytoplasm with hairy-like projections and express CD11c, CD25, CD103, and CD123 [Indian J Hematol Blood Transfus. 2014;30(Suppl 1):413-7]. Loss of CD123 in HCL has been rarely reported in the literature [Am J Hematol. 2019;94(12):1413-22]. We describe a unique case of a COVID-19-positive male who presented with severe respiratory symptoms, deteriorated quickly, and was intubated. Workup of severe progressive pancytopenia and bone marrow examination revealed HCL without splenomegaly and with atypical unusual loss of CD123. To our knowledge, this is the first case of CD123-negative HCL without splenomegaly associated with COVID-19 infection as the initial presentation.
2019冠状病毒病(COVID-19)大流行构成了严重威胁,并且已有关于其不同临床表现及并发症的报道。高龄以及合并症,如糖尿病、高血压或心脏病,会增加COVID-19病情严重程度及死亡的风险因素[《新英格兰医学杂志》。2020年;382(18):1708 - 20以及《柳叶刀呼吸医学》。2020年5月;8(5):475 - 81]。有人提出,与非癌症患者相比,癌症患者感染病毒后发生严重事件的发生率显著更高,包括入住重症监护病房、需要辅助通气,甚至死亡[《柳叶刀肿瘤学》。2020年;21(3):335 - 7]。还有报道称,癌症患者感染严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的可能性似乎是常人的两倍[《美国医学会杂志·肿瘤学》。2020年;6(7):1108 - 10]。毛细胞白血病(HCL)是一种罕见的B细胞淋巴增殖性疾病,患者通常表现为血细胞减少,80 - 90%的患者有明显脾肿大,循环白血病细胞、骨髓浸润以及存在BRAF V600E体细胞突变[《印度血液学与输血杂志》。2014年;30(增刊1):413 - 7]。白血病细胞通常有中央核和丰富的细胞质,带有毛状突起,并表达CD11c、CD25、CD103和CD123[《印度血液学与输血杂志》。2014年;30(增刊1):413 - 7]。HCL中CD123缺失在文献中鲜有报道[《美国血液学杂志》。2019年;94(12):1413 - 22]。我们描述了一例独特的病例,一名COVID-19阳性男性患者,出现严重呼吸道症状,病情迅速恶化并接受了插管治疗。对严重进行性全血细胞减少的检查及骨髓检查显示为HCL,无脾肿大,且CD123出现非典型异常缺失。据我们所知,这是首例以CD123阴性且无脾肿大的HCL作为初始表现并与COVID-19感染相关的病例。